The drug pazopanib (Votrient) extended the lives of a small group of kids with Ewing sarcoma, which causes cancerous tumors ...

Inhibrx Biosciences’ antibody ozekibart has notched a key phase 2 win in a rare bone cancer that currently has no approved ...

BERLIN -- Administering bone-modifying agents (BMAs) every 24 weeks after long-term use was a safe and effective strategy for ...

Ewing sarcoma is one of the most common bone cancers seen in children, and if it spreads, it can be deadly. One study found ...

Inhibrx Biosciences, Inc. reports strong phase 2 results for ozekibart in chondrosarcoma, with new cancer data and key ...

Inhibrx Biosciences said on Thursday its experimental drug helped slow the progression of a rare and aggressive bone cancer ...

Bone cancer in the leg, while relatively uncommon, presents with specific warning signs that warrant immediate medical attention. Understanding these symptoms enables individuals to seek prompt ...

Dr. Matthew Matasar discusses why stem cell transplant is still a standard, life-saving option in blood cancers and how CAR-T ...

Men with recurrent prostate cancer following surgery or radiation therapy may now have a new chance to live longer. A massive ...